论文部分内容阅读
目的:分析研讨黄芪联合厄贝沙坦治疗高血压肾病的临床疗效和作用机制。方法:用随机抽签方式,从我院2015年4月至2016年6月期间收治的高血压肾病患者中,抽取80例纳入到讨论中,用随机数字法分组两组讨论,各40例,对照组接受厄贝沙坦治疗,研究组接受黄芪联合厄贝沙坦治疗,观察治疗状况,并对比。结果:研究组治疗总疗效87.50%高于对照组67.50%,组间数据有统计学意义(P<0.05)。对比治疗后尿素氮、血清肌酐指数,研究组优于对照组,数据有统计学意义(P<0.05);对比舒张压、收缩压指数,组间数据无统计学意义(P>0.05)。结论:临床治疗高血压肾病可考虑将黄芪和厄贝沙坦药物联合使用,疗效突出,在改善肾功能和血压水平上作用明显,预后良好,值得应用和推广。
Objective: To analyze the clinical efficacy and mechanism of Astragalus combined with irbesartan in the treatment of hypertensive nephropathy. Methods: 80 cases of hypertensive nephropathy patients admitted from April 2015 to June 2016 in our hospital were randomly divided into two groups: random number method, 40 cases, control group Group received irbesartan treatment, the study group received astragalus combined irbesartan treatment, observation of treatment, and compared. Results: The total curative effect of study group was 87.50% higher than that of control group (67.50%). The data of the two groups were statistically significant (P <0.05). Comparing the post-treatment urea nitrogen and serum creatinine index, the study group was superior to the control group, the data was statistically significant (P <0.05); compared with the diastolic blood pressure and systolic blood pressure index, there was no significant difference between the two groups (P> 0.05). Conclusion: The clinical treatment of hypertensive nephropathy can be considered astragalus and irbesartan drug combination with outstanding curative effect in improving renal function and blood pressure levels, the effect is good, the prognosis is good, it is worth to apply and promote.